Skip to main content
SpringerLink
Log in

Perampanel tolerability “acceptable” in phase III trial

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ryvlin P, Lagae L, Unterberger I, Squillacote D, Yang H, Kumar D, Laurenza A.Perampanel as adjunctive therapy in patients with refractory partial-onset seizures: safety and tolerability analysis from a phase III trial. 65th Annual Meeting of the American Epilepsy Society: abstr. 2.236, 2 Dec 2011. Available from: URL: http://www.aesnet.org/go/publications/aes-abstracts

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perampanel tolerability “acceptable” in phase III trial. React. Wkly. 1384, 5 (2012). https://doi.org/10.2165/00128415-201213840-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213840-00018

Keywords

Search

Navigation